Happi Staff12.13.19
Flowerkist Incorporated has entered into a proprietary agreement with Dabur Research Foundation (DRF) to develop and launch a wide range of 100% hemp-based CBD infused topical products with its patent-pending “Rapid Penetration Technology.” Under the terms of the agreement, DRF will provide formulation development as well as verification of safety and efficacy. Flowerkist will be responsible for global distribution and marketing of the products. Althea DRF, an affiliated organization of Dabur Research Foundation, has also entered into an agreement to invest an undisclosed amount in Flowerkist.
Dabur Research Foundation (DRF) is a GLP and AAALAC accredited product development and research organization headquartered in Delhi, India. It was established in 1979 as an in-house research and development arm for new innovations for Dabur. Today, Dabur annual revenue exceeds $1 billion and is traded on the NSE.
Entering an Emerging Market
“In 2016 we saw the emerging market in medical cannabis,” commented co-founder/CEO of Flowerkist, Barry Clark, “and decided to focus on topical hemp-based products and avoid any association with psychoactive substances (i.e., THC).”
“However, until the Farm Bill was passed in December 2018, which made 100% hemp-based products federally legal,” he went on to say, “we had multiple challenges in attracting the optimal resources.”
“We are very excited about the opportunity to be a partner and, through Althea DRF, an investor in Flowerkist,” said Dr. Manu Jaggi, COO of DRF. “For the last several years, we have been investigating the biology of cannabinoids including CBD and working on various technologies to overcome challenges in delivery of efficacious products in this space. What attracted our attention was Flowerkist’s superior vision on how to best capitalize on this emerging global category.”
Dabur Research Foundation (DRF) is a GLP and AAALAC accredited product development and research organization headquartered in Delhi, India. It was established in 1979 as an in-house research and development arm for new innovations for Dabur. Today, Dabur annual revenue exceeds $1 billion and is traded on the NSE.
Entering an Emerging Market
“In 2016 we saw the emerging market in medical cannabis,” commented co-founder/CEO of Flowerkist, Barry Clark, “and decided to focus on topical hemp-based products and avoid any association with psychoactive substances (i.e., THC).”
“However, until the Farm Bill was passed in December 2018, which made 100% hemp-based products federally legal,” he went on to say, “we had multiple challenges in attracting the optimal resources.”
“We are very excited about the opportunity to be a partner and, through Althea DRF, an investor in Flowerkist,” said Dr. Manu Jaggi, COO of DRF. “For the last several years, we have been investigating the biology of cannabinoids including CBD and working on various technologies to overcome challenges in delivery of efficacious products in this space. What attracted our attention was Flowerkist’s superior vision on how to best capitalize on this emerging global category.”